Shoji M
Department of Neurology, Gunma University, School of Medicine.
Rinsho Shinkeigaku. 2000 Dec;40(12):1234-6.
Rapid growth of dementia patients prompts improvement of medical and care systems. For this reason, biological markers for Alzheimer's disease are necessary, which enable us detect Alzheimer's disease before onset of dementia and evaluate drug effects on evidence based procedure. Here, we summarized the developing field of biological markers and reported recent results of large-scale multicenter study of CSF tau and A beta for clinical practice.
痴呆症患者数量的快速增长促使医疗和护理系统不断改进。因此，阿尔茨海默病的生物标志物十分必要，它能使我们在痴呆症发病前检测出阿尔茨海默病，并根据循证程序评估药物疗效。在此，我们总结了生物标志物的发展领域，并报告了近期关于脑脊液tau蛋白和淀粉样β蛋白的大规模多中心临床研究结果。
